# US 2016/0251680 A1 · Dry transfection compositions and methods for making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251680 A1
- Document ID: US20160251680A1
- Status: Published application
- Kind: A1
- Application number: 15/026,121
- Filed: 2014-10-23
- Published: 2016-09-01
- Earliest claimed: 2013-11-05
- Applicants: Clontech Laboratories, Inc.
- Inventors: Thomas Patrick Quinn; Sayantan Mitra
- Web page: https://patentgrep.com/patent/US20160251680A1

## CPC

- C12N 15/85: for animal cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 2740/15021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/15022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Dry, e.g., lyophilized, polymeric transfection agent compositions are provided. The dry compositions include a polymeric transfection agent and a buffer. In some instances, the compositions further include one or more nucleic acids. Also provided are methods of making and using the compositions, as well as kits including the compositions.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A dry composition comprising:
a polymeric transfection agent; and
a buffer.

### Claim 17 (depends on 16)

The dry composition according to claim 16, wherein the dry composition is a lyophilized composition.

### Claim 18 (depends on 16)

The dry composition according to claim 16, wherein the polymeric transfection agent comprises a heteropolymer.

### Claim 19 (depends on 18)

The dry composition according to claim 18, wherein the polymeric transfection agent comprises a poly(β-amino esters) and salts and derivatives thereof.

### Claim 20 (depends on 16)

The dry composition according to claim 16, wherein the composition is cryoprotectant free.

### Claim 21 (depends on 16)

The dry composition according to claim 16, wherein the composition comprises a nucleic acid.

### Claim 22 (depends on 21)

The dry composition according to claim 21, wherein the nucleic acid comprises an expression cassette.

### Claim 23 (depends on 22)

The dry composition according to claim 22, wherein the expression cassette comprises a protein coding sequence.

### Claim 24 (depends on 23)

The dry composition according to claim 23, wherein the protein comprises a viral protein.

### Claim 25 (depends on 24)

The dry composition according to claim 24, wherein the composition comprises nucleic acids encoding two or more viral proteins.

### Claim 26 (depends on 25)

The dry composition according to claim 25, wherein the composition comprises nucleic acids encoding all requisite proteins for producing a viral particle.

### Claim 27 (depends on 26)

The dry composition according to claim 26, wherein the nucleic acids are present on the same vector.

### Claim 28 (depends on 27)

The dry composition according to claim 27, wherein the nucleic acids are present on different vectors.

### Claim 29 (depends on 26)

The dry composition according to claim 26, wherein the viral particle is a retroviral particle.

### Claim 30 (depends on 22)

The dry composition according to claim 22, wherein the expression cassette is inducible.

### Claim 31

A method of introducing a nucleic acid into a cell, the method comprising:
a) combining:
i) a dry composition comprising a polymeric transfection agent and a buffer;
ii) a solvent; and
iii) the nucleic acid;
to produce a liquid transfection solution; and
b) contacting the liquid transfection solution with the cell to introduce the nucleic acid into the cell.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the polymeric transfection agent comprises a heteropolymer.

### Claim 33

A kit comprising:
a container; and
a dry composition comprising:
a polymeric transfection agent; and
a buffer;
present in the container.

### Claim 34 (depends on 33)

The kit according to claim 33, wherein the kit further comprises a vector comprising a cloning site operably connected to a promoter.

### Claim 35 (depends on 34)

The kit according to claim 34, wherein the vector further comprises a viral packaging sequence.
